ALNY Q1 2022 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$213M+20.1% YoY

Gross Profit

$178M83.3% margin

Operating Income

-$147M-68.8% margin

Net Income

-$240M-112.7% margin

EPS (Diluted)

$-2.00

QoQ Revenue Growth

-17.5%

Cash Flow

Operating Cash Flow

-$171M

Free Cash Flow

-$189M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$3.4B

Total Liabilities

$3.0B

Stockholders' Equity

$401M

Cash & Equivalents

$534M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$213M	$178M	+20.1%
Gross Profit	$178M	$147M	+21.2%
Operating Income	-$147M	-$186M	+21.2%
Net Income	-$240M	-$200M	-20.0%

Revenue Segments

Product

$187M100%

Royalty

$442,0000%

Geographic Segments

Europe

$8M56%

UNITED STATES

$5M37%

Non-US Or Europe

$1M7%